In the latest session, VBI Vaccines Inc. (NASDAQ: VBIV) closed at $0.55 down -8.52% from its previous closing price of $0.60. In other words, the price has decreased by -$0.0513 from its previous closing price. On the day, 989318 shares were traded. VBIV stock price reached its highest trading level at $0.6199 during the session, while it also had its lowest trading level at $0.5331.
For a deeper understanding of VBI Vaccines Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.60 and its Current Ratio is at 2.80. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.58.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Raymond James on November 11, 2022, Downgraded its rating to Outperform and sets its target price to $2 from $5 previously.
On February 25, 2021, Jefferies started tracking the stock assigning a Buy rating and target price of $7.Jefferies initiated its Buy rating on February 25, 2021, with a $7 target price.
For the stock, the TTM Price-to-Sale (P/S) ratio is 158.14 while its Price-to-Book (P/B) ratio in mrq is 1.72.
Stock Price History:
Over the past 52 weeks, VBIV has reached a high of $1.87, while it has fallen to a 52-week low of $0.36. The 50-Day Moving Average of the stock is 0.5168, while the 200-Day Moving Average is calculated to be 0.8339.
For the past three months, VBIV has traded an average of 1.01M shares per day and 1.11M over the past ten days. A total of 258.26M shares are outstanding, with a floating share count of 204.57M. Insiders hold about 0.52% of the company’s shares, while institutions hold 44.40% stake in the company. Shares short for VBIV as of Oct 13, 2022 were 13.93M with a Short Ratio of 11.85M, compared to 14.67M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 5.39% and a Short% of Float of 7.28%.
There are 3 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.08 for the current quarter, with a high estimate of -$0.08 and a low estimate of -$0.08, while EPS last year was -$0.06. The consensus estimate for the next quarter is -$0.08, with high estimates of -$0.06 and low estimates of -$0.09.
Analysts are recommending an EPS of between -$0.29 and -$0.42 for the fiscal current year, implying an average EPS of -$0.37. EPS for the following year is -$0.26, with 3 analysts recommending between -$0.24 and -$0.29.
A total of 3 analysts believe the company’s revenue will be $1.29M this quarter.It ranges from a high estimate of $1.5M to a low estimate of $880k. As of the current estimate, VBI Vaccines Inc.’s year-ago sales were $107k, an estimated increase of 1,105.60% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $2.1M, an increase of 2,492.60% over than the figure of $1,105.60% in the same quarter last year. There is a high estimate of $2.8M for the next quarter, whereas the lowest estimate is $1.51M.
A total of 3 analysts have provided revenue estimates for VBIV’s current fiscal year. The highest revenue estimate was $4.8M, while the lowest revenue estimate was $2.86M, resulting in an average revenue estimate of $3.92M. In the same quarter a year ago, actual revenue was $631k, up 521.20% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $20.12M in the next fiscal year. The high estimate is $23.4M and the low estimate is $16.38M. The average revenue growth estimate for next year is up 413.30% from the average revenue estimate for this year.